Recycling side-effects into clinical markers for drug repositioning
about
Drug repositioning by kernel-based integration of molecular structure, molecular activity, and phenotype dataConstruction of drug network based on side effects and its application for drug repositioningInferences of drug responses in cancer cells from cancer genomic features and compound chemical and therapeutic propertiesComputational drug repositioning: from data to therapeutics.Computational drug repositioning through heterogeneous network clustering.A chemo-centric view of human health and diseaseDrug repositioning for non-small cell lung cancer by using machine learning algorithms and topological graph theory.Cogena, a novel tool for co-expressed gene-set enrichment analysis, applied to drug repositioning and drug mode of action discoveryLarge-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles.Computational Study of Drugs by Integrating Omics Data with Kernel Methods.Combining automatic table classification and relationship extraction in extracting anticancer drug-side effect pairs from full-text articles.PhenoPredict: A disease phenome-wide drug repositioning approach towards schizophrenia drug discoveryA genomics-based systems approach towards drug repositioning for rheumatoid arthritis.From protein interaction networks to novel therapeutic strategies.The role of drug profiles as similarity metrics: applications to repurposing, adverse effects detection and drug-drug interactions.Towards drug repositioning: a unified computational framework for integrating multiple aspects of drug similarity and disease similarity.An Integrative Drug Repurposing Pipeline: Switching Viral Drugs to Breast Cancer.Label Propagation Prediction of Drug-Drug Interactions Based on Clinical Side Effects.Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition.Systematic prediction of drug combinations based on clinical side-effects.
P2860
Q28534990-7390DE67-B811-4359-9C95-9D4784674ED6Q28539501-4A73C4BC-DBB3-46F3-A93B-E2D0420E1A77Q28829729-6C67B4D4-E8C2-4C41-B4F6-32E94049A3F9Q30594820-5B012922-E2B2-4857-B0CB-AE9F01F0AF84Q35101970-59CC8EBF-BC29-438A-BB82-BA3C0C0AAF4EQ35114229-C2EB31F5-9B9A-481C-8A5C-28964065B9C1Q35906092-317FB3D5-A842-4068-B1BB-95201732D606Q36032797-2C8DD970-05CE-4844-90A7-256908A8F986Q36092046-28FB4AAC-836F-475A-A2EA-D2B52926DBC5Q36092098-7E951180-630D-438B-84D1-ED2AD8DF3645Q36100483-8372A3AA-BB4A-4F97-A7F3-5B446F85ED7AQ36109996-0B9569E0-D7C7-444E-B6D7-DCEEAD1C42D4Q36111821-3363EFD8-BABA-4B79-9CBE-42B887394A08Q38008992-D017FD70-EB52-4857-8209-15B9C023975BQ38856712-B729E3CE-7DC2-4A1E-B220-26A9EEC64CBCQ40272650-479946A7-B9D5-4677-A2A5-CED16A672F52Q40469984-5C18D3CC-0593-4156-AEB4-7212960D929FQ40713580-1CBAACF9-8EBA-463E-BBAF-895F941A6DFDQ41575123-0C1CF6FD-6E17-4752-A95A-AD44DDFE05A1Q42050971-091E522B-B823-4775-8148-A1FCC1EF51A3
P2860
Recycling side-effects into clinical markers for drug repositioning
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Recycling side-effects into clinical markers for drug repositioning
@ast
Recycling side-effects into clinical markers for drug repositioning
@en
Recycling side-effects into clinical markers for drug repositioning
@nl
type
label
Recycling side-effects into clinical markers for drug repositioning
@ast
Recycling side-effects into clinical markers for drug repositioning
@en
Recycling side-effects into clinical markers for drug repositioning
@nl
prefLabel
Recycling side-effects into clinical markers for drug repositioning
@ast
Recycling side-effects into clinical markers for drug repositioning
@en
Recycling side-effects into clinical markers for drug repositioning
@nl
P2860
P3181
P356
P1433
P1476
Recycling side-effects into clinical markers for drug repositioning
@en
P2093
Miquel Duran-Frigola
P2860
P2888
P3181
P356
10.1186/GM302
P407
P50
P577
2012-01-27T00:00:00Z
P5875
P6179
1028257480